Another experimental covid-19 vaccine has shown promising early results

Marco Green
July 3, 2020

"We are encouraged by the clinical data of BNT162b1, one of four mRNA constructs we are evaluating clinically, and for which we have positive, preliminary, topline findings", said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer.

United States stocks closed mixed on Wednesday as investors weighed COVID-19 vaccine progress against a spike in national virus cases.

The initial part of the trial studied 45 healthy adults ages 18-55.

An ongoing collaborative Phase1/2 clinical trial in the USA and involving 45 participants aged between 18 and 55 have received either 10, 30, or 100 microgram doses of the drug BNT162b1 vaccine or a placebo over 21 days.

The ongoing Phase I/II trial, taking place in the U.S., is testing BNT162b1, an mRNA vaccine candidate against the novel coronavirus.

In the phase 1/2 trial, all 24 patients that received the two lower doses (10 micrograms and 30 micrograms) showed elevated antibody levels, and those responses, on average, were above the levels observed in the comparison panel of 38 patients that had naturally contracted SARS-CoV-2.

More specifically, the BNT162b1 vaccine candidate in current trials clinically incorporates nucleoside modified RNA and encodes the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein - a key target for virus-neutralizing antibodies.

The companies said the preliminary data, plus additional preclinical and clinical data now being generated, will help them determine a dose level and select among multiple vaccine candidates for a global Phase IIb/III safety and efficacy trial in, potentially, up to 30,000 healthy participants-a study set to start later this month. Aside from this data, the researchers also observed a common local reaction of injection site pain and low-grade fever which was more common after the second dose than the first dose.

According to the Johns Hopkins University, as of July 2, the world was more than 10.6 million cases of coronavirus.

Pfizer and BioNTech's joint development program includes three other vaccine candidates, but Wednesday's, called BNT162b1, is the furthest along in the process.

The study noted that there was no serious adverse events reported by the patients. "We look forward to publishing our clinical data in a peer-reviewed journal as quickly as possible", she added.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER